Brief: GeNeuro Regains Worldwide Rights Ex US And Japan To GNbAC1 In Multiple Sclerosis From Servier

Geneuro SA

18/09/2018 06:37

Sept 18 (Reuters) - GENEURO SA  GNRO.PA :
    * GENEURO REGAINS WORLDWIDE RIGHTS EX US AND JAPAN TO GNBAC1 IN MULTIPLE SCLEROSIS FROM
SERVIER
    * BASED ON POSITIVE PHASE IIB 12-MONTH RESULTS, GENEURO WILL PURSUE FURTHER DEVELOPMENT AND
WORLDWIDE PARTNERING OPTIONS
    * SERVIER DECLINES OPTION TO LICENSE AND TO FURTHER FUND DEVELOPMENT OF GNBAC1 IN MS
    * SERVIER WILL CONTINUE TO SUPPORT GENEURO AS A SHAREHOLDER
    * GENEURO IS ALSO CONTINUING ITS PHASE IIA CLINICAL TRIAL WITH GNBAC1 IN 60 RECENTLY
DIAGNOSED
ADULTS WITH TYPE I DIABETES.
    * GNBAC1 TOP-LINE RESULTS EXPECTED BY END OF SEPTEMBER 2018
    * XTENSION ANGEL-MS STUDY, FUNDED BY SERVIER, WILL BE SHORTENED. ITS TERMINATION WILL HAVE
NO
FINANCIAL IMPACT FOR GENEURO

Source text for Eikon:  ID:nBw47dTPta 
Further company coverage:  GNRO.PA 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))